Dendritic Cell (DCs) Based Neoantigen Cancer Vaccines
Creative Biolabs leads a top-class vaccine development teams of experienced professionals from all over the world, and is also harnessed with state-of-the-art facilities, equipment as well as well-trained laboratory staff. Over 10 years of accumulations in vaccine development, we are now able to engage in the field of cancer vaccine development from all aspects.
Background
Vaccines targeting neoantigen enable individualized treatment of cancer patients a reality, which may be the most effective and safe cancer vaccine strategy. However, in order to achieve the broad clinical application of the neoantigen vaccine, accurately predicting the antigenic neoantigen and selecting the appropriate delivery strategy to exert the efficacy of neoantigen are two issues that must be considered and addressed in the development of a successful neoantigen-based cancer vaccine. For the prediction and identification of neoantigen, with the advancement of genome sequencing technology, the improvement of MHC epitope database and the continuous development of prediction algorithms, it has become possible to screen and identify tumor neoantigen in patients.
Dendritic Cell (DCs) Based Neoantigen Cancer Vaccines
For the delivery of selected neoantigen to professional antigen-presenting cells (APCs) to elicit robust and potent anti-cancer T cell responses, a range of strategies have also been put forward. Synthetic long peptides (SLPs) and ex vivo-pulsed DC-based neoantigen vaccines are two representative methods. The preparation of DC-based neoantigen vaccine is usually to isolate immature dendritic cells from monocytes in a patient, co-culture with irradiated feeder cells in the presence of an adjuvant to maturity. And then the DCs are pulsed by predicted, long peptides of the identified epitopes to load HLA class I or II molecules on their surface. In addition to the use of long peptides, transfection of DCs with mRNA encoding neoantigen is also a method of producing DC-based neoantigen cancer vaccines. The results of a small clinical trial of this vaccine showed the increased strength of the existing neoantigen-specific immune response in patients after receiving peptide-pulsed mature DCs.
Our Services for Development of DCs-based Neoantigen Cancer Vaccines
- Neoantigen or neoepitope prediction
- Design and preparation of DCs-based neoantigen cancer vaccine
- Formulation development and optimization
- Evaluation and analysis of efficacy and safety profiles of vaccine candidate
The development of successful cancer vaccines needs comprehensive understanding of immunology and intense labor-input. Experts from Creative Biolabs have solid vaccine research and development background and have launched a series of available technologies and platforms based on cutting-edge discoveries. We are able to provide a string of one-stop services for the development of dendritic cell-based neoantigen cancer vaccines. If you have any needs or doubts, please contact us!
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
